The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01F | Monoclonal antibodies and antibody drug conjugates | |
| 4 | L01FX | Other monoclonal antibodies | |
| 5 | L01FX32 |
| Active Ingredient | Description | |
|---|---|---|
| Elranatamab |
Elranatamab is a bi-specific T-cell engaging antibody that binds CD3-epsilon on T-cells and B-cell maturation antigen (BCMA) on plasma cells, plasmablasts, and multiple myeloma cells. Binding of elranatamab to BCMA on tumour cells and CD3 on T-cells is independent of native T-cell receptor (TCR) specificity or reliance on major histocompatibility (MHC) Class 1 molecules. Elranatamab activated T-cells, led to proinflammatory cytokine release, and resulted in multiple myeloma cell lysis. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ELREXFIO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ELREXFIO Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
